How do researchers decide early clinical trials?

Medicine, Health Care and Philosophy

Volumn 19, Issue 2, 2016, Pages 191-198

  Grankvist, Hannah ^a   Kimmelman, Jonathan ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Decision making; Phase 1 trials; Policy; Research ethics; Risk benefit; Translational research

Indexed keywords

CLINICAL TRIAL (TOPIC); DECISION MAKING; DEVICES; ETHICS; HUMAN; PERSONNEL; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; PSYCHOLOGY; PUBLIC POLICY; RISK ASSESSMENT;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; DECISION MAKING; HUMANS; PUBLIC POLICY; RESEARCH PERSONNEL; RISK ASSESSMENT;

EID: 84971325697     PISSN: 13867423     EISSN: 15728633     Source Type: Journal    
DOI: 10.1007/s11019-016-9685-6     Document Type: Article

References (42)

1. Alper, J. 2009. Geron gets green light for human trial of ES-derived product. Nature Biotechnology 27(3): 213–214.
2. ASCO (American Society of Clinical Oncology). 1997. Critical role of phase I clinical trials in cancer treatment. Journal of Clinical Oncology 15(2): 853–859.
3. Casper, M.J. 1998. The making of the unborn patient: A social anatomy of fetal surgery. New Brunswick, NJ: Rutgers University Press.
4. CIOMS (Council for International Organizations of Medical Sciences). 2002. International ethical guidelines for biomedical research involving human subjects. Geneva.
5. Couzin, J., and G. Vogel. 2004. Cell therapy. Renovating the heart. Science 304(5668): 192–194.
6. Deakin, C.T., I.E. Alexander, C.A. Hooker, and I.H. Kerridge. 2013. Gene therapy researchers’ assessment of risk and perception of risk acceptability in clinical trials. Molecular Therapy 21(4): 806–813.
7. EMA (European Medicines Agency). 2007. Guidelines on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf. Accessed 10 Oct 2014.
8. FDA (Food and Drug Administration). 2013. In Guidance for industry: Preclinical assessment of investigational cellular and gene therapy products, ed. Services USDoHH.
9. FDA (Food and Drug Administration). 1995. In Guidance for industry: Content and format of investigational new drug applications (INDs) for phase I studies of drugs, including well-characterized, therapeutic, biotechnology-derived products, ed. Services USDoHH.
10. Fox, R.C., and J.P. Swazey. 1992. Spare parts: Organ replacement in American society. New York, NY: Oxford University Press.
11. Geison, G.L. 1995. The private science of Louis Pasteur. Princeton, Chichester, West Sussex, NJ: Princeton University Press.
12. Grady, D., and G. Kolata. 2003. Gene therapy used to treat patients with Parkinson’s. New York Times 19 August.
13. Grankvist, H. 2011. Making doable problems within controversial science: US and Swedish Scientists’ experience of gene transfer research. Linköping: Linköping Studies in Arts and Science, LiU-tryck.
14. Greaves, P., A. Williams, and M. Eve. 2004. First dose of potential new medicines to humans: How animals help. Nature Reviews Drug Discovery 3(3): 226–236.
15. Halpern, S.A. 2004. Lesser harms: The morality of risk in medical research. Chicago, IL: The University of Chicago Press.
16. Henderson, V.C., J. Kimmelman, D. Fergusson, J.M. Grimshaw, and D.G. Hackam. 2013. Threats to validity in the design and conduct of preclinical efficacy studies: A systematic review of guidelines for in vivo animal experiments. PLoS Medicine 10(7): e1001489.
17. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). 2009. ICH harmonised tripartite guideline: NonClinical evaluation for anticancer pharmaceuticals—S9. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf. Accessed 10 Oct 2014.
18. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). 2000. ICH harmonised tripartite guideline: Safety pharmacological studies for human pharmaceuticals—S7A. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf. Accessed 10 Oct 2014.
19. ISSCR (International Society for Stem Cell Research). 2008. Guidelines for the clinical translation of stem cells. http://www.isscr.org/docs/default-source/clin-trans-guidelines/isscrglclinicaltrans.pdf. Accessed 10 Oct 2014.
20. Kilkenny, C., N. Parsons, E. Kadyszewski, M.F.W. Festing, I.C. Cuthill, D. Fry, J. Hutton, and D.G. Altman. 2009. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4(11): e7824.
21. Kimmelman, J., and V. Henderson. 2015. Assessing risk/benefit for trials using preclinical evidence: A proposal. Journal of Medical Ethics. doi:10.1136/medethics-2015-102882.
22. Kimmelman, J., and A.J. London. 2011. Predicting harms and benefits in translational trials: Ethics, evidence, and uncertainty. PLoS Medicine 8(3): e1001010.
23. Lapchak, P.A., J.H. Zhang, and L.J. Noble-Hausslein. 2013. RIGOR guidelines: Escalating STAIR and STEPS for effective translational research. Translational Stroke Research 4(3): 279–285.
24. London, A.J., J. Kimmelman, and M.E. Emborg. 2010. Beyond access vs. protection in trials of innovative therapies. Science 328(5980): 829–830.
25. Lowy, I. 1996. Between bench and bedside: Science, healing and interleukin-2 in a cancer ward. Cambridge, MA: Harvard University Press.
26. Markman, M. 2006. ‘Therapeutic intent’ in phase 1 oncology trials: A justifiable objective. Archives of Internal Medicine 166(14): 1446–1448.
27. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1978. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Washington, DC: US Government Printing Office. (DHEW Publication # (OS) 78-0012).
28. Newell, D.R., S.S. Burtless, B.W. Fox, D.I. Jodrell, and T.A. Connors. 1999. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. British Journal of Cancer 81(5): 760–768.
29. Nuremberg Military Tribunals. 1949. Trials of war criminals before the Nuremberg military tribunals under control council law, 181–182. Washington, DC: US Government Printing Office.
30. Prinz, F., T. Schlange, and K. Asadullah. 2011. Believe it or not: How much can we rely on published data on potential drug targets? Nature Review Drug Discovery 10(9): 712.
31. Ross, L. 2006. Phase 1 research and the meaning of direct benefit. Journal of Pediatrics 149(Suppl 1): S20–S24.
32. RIGOR. 2012. Improving the quality of NINDS-supported research through rigorous study design and transparent reporting. http://www.ninds.nih.gov/funding/transparency_in_reporting_guidance.pdf. Accessed 14 Oct 2014.
33. Savitz, S.I., M. Chopp, R. Deans, S.T. Carmichael, D. Phinney, L. Wechsler, and The STEPS Particioants. 2011. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke 42(3): 825–829.
34. Sena, E.S., H.B. van der Worp, P.M.W. Bath, D.W. Howells, and M.R. Macleod. 2010. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biology 8(3): e1000344.
35. STAIR (Stroke Therapy Academic Industry Roundtable). 2001. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32(7): 1598–1606.
36. STAIR (Stroke Therapy Academic Industry Roundtable). 1999. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30(12): 2752–2758.
37. van Luijn, H.E.M., A.W. Musschenga, R.B. Keus, W.M. Robinson, and N.K. Aaronson. 2002. Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members. Annuals of Oncology 13: 1307–1313.
38. Wechsler, L.R., D. Steindler, C. Borlongan, M. Chopp, S. Savitz, R. Deans, L. Caplan, D. Hess, R.W. Mays, and The STEPS Participants. 2009. Stem cell therapy as an emerging paradigm for stroke (STEPS): Bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 40(2): 510–515.
39. WMA (World Medical Association). 2013. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Journal of the American Medical Association 301: 2191–2194.
40. Yap, T.A., S.K. Sandhu, P. Workman, and J.S. de Bono. 2010. Envisioning the future of early anticancer drug development. Nature Reviews Cancer 10(7): 514–523.
41. 21 CFR 314. 2015. Food and drugs—Applications for FDA approval to market a new drug. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9. Accessed 3 Sept 2015.
42. 21 CFR 601. 2015. Food and drugs—Licensing. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.8. Accessed 3 Sept 2015.